Skip to main content
. Author manuscript; available in PMC: 2008 Oct 7.
Published in final edited form as: Mol Cancer Ther. 2007 Aug;6(8):2188–2197. doi: 10.1158/1535-7163.MCT-07-0235

Figure 3. Rapamycin blocks mTOR signaling in primary tumors without affecting c-Neu/ErbB2 activation.

Figure 3

A. Western blot analysis indicates that rapamycin does not alter phosphorylation of Akt in tumors. Whole cell lysates (100 μg) of primary MMTV-c-Neu tumors were evaluated by immunoblots that were sequentially probed using antibodies directed against phospho-Akt and total Akt. B. Rapamycin does not affect the relative levels of phosphorylated mTOR in tumors. Western blots were sequentially probed using antibodies directed against phospho-mTOR (serine 2448) and total mTOR. C/D. Rapamycin decreases phosphorylation of Ribosomal Protein S6 in tumors. Representative sections (200X, bar 50μM) of immunohistochemical staining of cytoplasmic phosphorylated Ribosomal Protein S6 (serine 235/236) in primary tumors collected from vehicle (C) and rapamycin (D) treated mice.